Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...

RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...

RSV infections affect a significant number of children under age 5, with considerable disease burden in primary care and emergency departments.

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...

Older adults now have access to two approved vaccines, called Arexvy and Abrysvo. Guidance from the National Advisory Committee on Immunization (NACI) recommends RSV vaccination for any adults aged 75 ...

The arrival of cooler weather and people gathering indoors can lead to the increased spread of COVID-19, influenza and ...

Bronchiolitis alarm in children, there is a life-saving drug but not all Regions can purchase it. The seasonal epidemic of ...

The following is a summary of “Respiratory viral infections from 2015 to 2022 in the HIVE cohort of American households: Incidence, illness characteristics, and seasonality,” published in the August ...

Sanofi is shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and Prevention for its Vaccines for ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

The federal government will again be distributing free COVID-19 tests to U.S. households. Here's when and how to order them in Texas.